Last reviewed · How we verify
Prepandrix™
Prepandrix is an inactivated split-virion influenza vaccine that stimulates the immune system to produce antibodies against pandemic H5N1 influenza virus strains.
Prepandrix is an inactivated split-virion influenza vaccine that stimulates the immune system to produce antibodies against pandemic H5N1 influenza virus strains. Used for Pandemic influenza H5N1 prevention in adults.
At a glance
| Generic name | Prepandrix™ |
|---|---|
| Also known as | GlaxoSmithKline [GSK] Biologicals' A/Indonesia/5/2005 (H5N1) (pre-) pandemic influenza adjuvanted vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Target | H5N1 influenza virus surface antigens (hemagglutinin and neuraminidase) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated H5N1 influenza virus particles that have been chemically treated and split to reduce reactogenicity while preserving immunogenicity. Upon administration, these viral antigens are recognized by the immune system, triggering both humoral (antibody) and cellular immune responses that provide protection against infection with H5N1 influenza. The vaccine was developed in preparation for potential pandemic influenza outbreaks caused by H5N1 strains.
Approved indications
- Pandemic influenza H5N1 prevention in adults
Common side effects
- Injection site reactions (pain, redness, swelling)
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prepandrix™ CI brief — competitive landscape report
- Prepandrix™ updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI